Heart Failure For Example Fluid Overload

3

Review clinical trials related to Heart Failure For Example Fluid Overload. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Detecting the Undetected: Heart Failure Screening at the Lymphoedema Point of Care

Heart failure affects more people than the four most common cancers combined. When identified early, management is more straightforward, preventing complications, hospitalisations, and fatalities. Breathlessness and fatigue are cardinal symptoms of heart failure that can present in a number of conditions. As a result, leg swelling, the third cardinal symptom, is the first noted in many people. The presence of leg swelling leads to patients being seen in lymphoedema clinics before the need for cardiology investigation has been identified. Lymphoedema is the presence of chronic oedema as a result of congenital abnormalities, inflammation, infection, trauma, or cancer and its treatments. The vast majority of lymphoedema patients have swelling in their legs. A recent study has shown that 9.4% lymphoedema patients need to be investigated for heart failure. At present, the need for investigation is identified by performing a laboratory blood test, which takes time to arrange and complete. An alternate point of care test can provide a result in 12-minutes at the lymphoedema appointment, and enable appropriate action to be taken. This can reduce the demands on primary care and shorten the chain of events to a specialist assessment, as well as reducing inappropriate referrals. This research, funded by NHS Wales Performance and Improvement, will perform a point of care test to screen for possible heart failure in lymphoedema clinics and establish the clinical utility by exploring the experiences of patients and staff involved and determining the health economic benefits. A supplementary aim is to compare the point of care test to the currently used laboratory test in a subsample to promote confidence in the test and support efforts to spread and scale across all health boards in Wales on completion.

Participants needed: 618
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Swansea Bay University Health BoardUpdated: Mar 27, 2026Locations: 1
Eligibility criteria

Patient of Swansea Bay University Health Board Lymphoedema Service. [+6]

All inclusion criteria not met. [+4]

Status: Recruiting

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

This clinical trial aims to determine whether a ReDS-guided treatment strategy is superior to the current standard of care for adults hospitalized with heart failure. Additionally, the study will evaluate the safety and cost-effectiveness of this approach. The study seeks to answer the following key questions: 1. Does the ReDS-guided strategy reduce the risk of cardiovascular events during the first month following hospital discharge? 2. What is the safety profile of this treatment strategy? Researchers will compare the ReDS-based strategy against the current standard of care. All participants will: * Undergo daily assessments using the ReDS device throughout their hospitalization. * Attend two follow-up visits post-discharge, scheduled at 2 weeks and 30 days.

Participants needed: 1,014
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y CajalUpdated: Mar 19, 2026Locations: 25
Eligibility criteria

Hospitalized due to heart failure as the main reason, including the presence of... [+1]

Height less than 150 cm or greater than 190 cm or body mass index (BMI) less tha... [+6]

Status: Not yet recruiting

Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling

The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients. The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.

Participants needed: 500
Trial details
Biological sex: AllType: ObservationalSponsor: University of ZurichUpdated: Sep 10, 2025Locations: 1Duration: 5 Years
Eligibility criteria

Female and Male, age ≥18 years at screening. [+3]

Active malignancy or history of cancer with ongoing treatment (e.g., chemotherap... [+4]